HDAC9 and myelodysplastic syndrome: Vorinostat (SAHA; suberoylanilide hydroxamic acid), an HDAC inhibitor, is approved by the FDA for the treatment of myelodysplastic syndrome and cutaneous T‐cell lymphoma.